pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Gohibic
drug · antibody
save

vilobelimab

Phase 2updated 3mo ago
by InflaRx NV🔗 ChEMBL
Phase 2
community read0 votes

Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for adult acute respiratory distress syndrome and 10 investigational indications.

targets

Complement C5

all catalysts(0)

nothing on the calendar yet

Trials studying vilobelimab

  • phase2JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)recruitingn=600
  • phase2JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimabrecruitingn=200
  • phase3Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosumterminatedn=54
  • phase2Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.terminatedn=30
  • phase2Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosumcompletedn=19

News(1)

  • Aura, Schrödinger trim workforces
    Follow along as BioSpace tracks job cuts and restructuring initiatives.
    biospace · 14h ago
brand
Gohibic
generic
vilobelimab
MOA
Complement C5 inhibitor
indication
Acute Respiratory Distress Syndrome
phase
phase_2
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 13m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?